Adhesion to stromal cells mediates imatinib resistance in chronic myeloid leukemia through ERK and BMP signaling pathways

Chronic myeloid leukemia (CML) is characterized by abnormal proliferation of myeloid cells which when untreated leads to bone marrow failure. Imatinib mesylate (IM) is the first line of therapy for treatment of CML and results in remission in most cases. However, a significant percentage of patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Atul, Bhattacharyya, Jina, Jaganathan, Bithiah Grace
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572702/
https://www.ncbi.nlm.nih.gov/pubmed/28842696
http://dx.doi.org/10.1038/s41598-017-10373-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572702/
https://www.ncbi.nlm.nih.gov/pubmed/28842696
http://dx.doi.org/10.1038/s41598-017-10373-3

Ejemplares similares